Immunotherapy trials for RCC

There are several ongoing trials to assess different immunotherapy agents in renal cell carcinoma as detailed below.

Immunotherapy Agent Treatment Phase Clinicaltrials.gov identifier
Anti-CTLA4
Ipilimumab Ipilimumab II NCT00057889
Anti-PD-1
Nivolumab

(BMS-936558)

Nivolumab + Sunitinib

Nivolumab + Pazopanib

Nivolumab + Ipilimumab

I NCT01472081
Nivolumab + Temsirolimus

Nivolumab + Irinotecan (Chemotherapy)

Nivolumab + Irinotecan/Capecitabine

I/II NCT02423954
Nivolumab (varied dose) II NCT01354431
Nivolumab

Nivolumab + Bevacizumab

Nivolumab + Ipilmumab

II NCT02210117
Nivolumab + Ipilimumab vs Sunitinib III NCT02231749
Nivolumab vs Everolimus III NCT01668784
Pembrolizumab

(MK-3475)

Pembrolizumab vs Pazopanib

Pembrolizumab + Pazopanib vs Pazopanib

I NCT02014636

 

Pembrolizumab + Radiation therapy I NCT02318771
Pembrolizumab + Axitinib I NCT02133742
Pembrolizumab + surgical resection I NCT02212730
Pembrolizumab + Ziv-Aflibercept I NCT02298959
Pembrolizumab + Bevacizumab I/II NCT02348008
Pembrolizumab

Pembrolizumab + Ipilimumab

Pembrolizumab + Pegylated IFN-2b

I/II NCT02089685
Pidilizumab

(CT-011)

Pidilizumab

Pidilizumab + Dendritic Cell (DC) vaccine

II NCT01441765
Anti-PD-L1
MPDL-3280A MPDL vs Sunitinib

MPDL + Bevacizumab vs Sunitinib

II NCT01984242
III NCT02420821
Dendritic cell vaccine
AGS-003 AGS-003 + surgical resection I NCT02170389
AGS-003 I/II NCT00272649
AGS-003 + Sunitinib II NCT00678119
AGS-003 vs AGS-003 + Sunitinib II NCT01482949
AGS-003 + Sunitinib vs Sunitinib III NCT01582672
Multi-peptide vaccine
IMA901 IMA901 + Sunitinib vs Sunitinib III NCT01265901